deep-phenotyping
(2)
Verantos
Verantos is a Menlo Park healthcare technology company that turns messy, fragmented patient records - including the clinical notes most platforms ignore - into research-grade real-world evidence (RWE) at scale. Using AI applied to the complete patient record and a rigorous focus on measured accuracy, completeness, and traceability, Verantos helps pharmaceutical companies, regulators, and health systems generate evidence that can hold up to FDA-grade scrutiny across every therapeutic area.
Dan Riskin
Dan Riskin is a physician-entrepreneur, trauma surgeon, and healthcare AI executive who founded Verantos in 2015 to generate high-validity real-world evidence from messy clinical data. A serial innovator who began coding at age 5 and sold software at 12, Riskin holds an MD from Boston University and an MBA from MIT, is board-certified in four specialties, and serves as Clinical Professor of Surgery at Stanford. His prior company Health Fidelity was acquired for more than $150 million. Today, Verantos powers regulatory and reimbursement decisions for major pharmaceutical companies by turning fragmented EHR data into research-grade evidence at scale.